The Global Single-cell Omics Market is witnessing significant growth driven by advancements in genomics technologies. Single-cell omics enables comprehensive analysis of individual cells through isolation of single cells followed by genome or transcriptome profiling. This provides valuable insights into inter-cellular heterogeneity present in tissues and tumors that are otherwise masked in bulk cell analyses.
Single-cell omics has revolutionized understanding of developmental biology, immunology, neuroscience and cancer. Technologies such as single-cell sequencing and single-cell multi-omics have enabled identification of cell types, tracing of cell lineages and characterization of rare cell populations. Interrogation of single cells has been instrumental in discovery of cell subtypes, understanding mechanisms of cell differentiation and plasticity. Advantages of single-cell analysis include ability to study complex cell mixtures without prior cell sorting, characterization of individual cells in spatial context within tissues and detection of rare circulating tumor cells.
Products for single-cell omics workflow include instruments, kits & reagents for single-cell isolation, RNA & DNA amplification, library preparation and next generation sequencing. Rapid advancements are being witnessed in microfluidics-based separation techniques, whole genome and whole transcriptome amplification methods, and integration of multi-omics approaches. Areas such as spatial transcriptomics are adding another dimension to single-cell studies.
The Global Single-cell Omics Market is estimated to be valued at US$ 1.63 BN in 2024 and is expected to exhibit a CAGR of 16.% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in The Global Single-Cell Omics Market are Bio-Rad Laboratories Inc., Agilent Technologies Inc., QIAGEN N.V., Thermo Fisher Scientific, Illumina Inc., Roche, Bio-Techne, and Pacific Biosciences. These companies offer comprehensive solutions for single-cell isolation, analysis and informatics. For instance, Bio-Rad offers the Chromium Single Cell platforms and ddSEQ Single Cell Analyzers while Fluidigm provides the C1 and Juno platforms.
The growing demand for personalized medicine and precision diagnostics is fueling adoption of single-cell omics approaches. Characterization of cellular heterogeneity enables development of targeted therapies and identification of novel drug targets. Single-cell analysis is crucial for understanding tumor evolution and developing effective immunotherapies and cancer biomarkers.
Expansion of the global omics market coupled with heavy investments in genomics R&D by both public and private players is driving the global single-cell omics market. Governments are increasingly funding single-cell studies to accelerate biomarker and drug discovery. Companies are also engaged in strategic collaborations and acquisitions to expand their product portfolios and geographic presence in high-growth Asian markets.
Market Key Trends
A major trend gaining traction in the global single-cell omics market is integration of multi-omics capabilities at single-cell level. Techniques such as single-cell genomics, epigenomics, proteomics and metabolomics are being combined to gain comprehensive insights through an individual cell. Multi-omics helps characterize cell state and plasticity more accurately. Thistrend is expected to continue with innovations facilitating simultaneous analysis of genome, transcriptome and proteome from the same single cell.
Porter’s Analysis
Threat of new entrants: Low set-up costs for new players, but established players have strong brand awareness and customer base.
Bargaining power of buyers: Large pharmaceutical and biotechnology companies have strong negotiating power as they can choose from various providers.
Bargaining power of suppliers: Suppliers of reagents and instruments have some negotiating power due to differentiated products.
Threat of new substitutes: Emerging technologies like genomics, proteomics and metabolomics pose little threat of substitution in short term.
Competitive rivalry: Intense competition among major players to gain market share.
Companies adopt strategies like acquisitions, partnerships and new product launches.
The global single-cell omics market is concentrated in North America. The region accounts for over 40% share due to presence of cutting-edge research facilities and availability of government and private funding for advanced research applications.
Asia Pacific region is poised to be the fastest growing market in the forecast period. Increased government investments in life science research, establishment of research institutes and growing biopharmaceutical industry are driving high demand for single-cell omics techniques in countries like China and India.
